September I

Liquid biopsy is offering a noninvasive, real-time, and personalized approach to tumor assessment, and is already revolutionizing the field of clinical oncology.

A recent phase 1/2 study revealed promising results, with an estimated 4-month intracranial progression-free survival rate of 70.7% with stereotactic radiosurgery with the combination of nivolumab and ipilimumab.

For large cell lymphomas, physicians typically use CT and positron emission tomography-computed tomography scans to look for signs of minimum residual disease when treatment is completed.

In the non–small cell lung cancer space, identifying the appropriate candidate to receive perioperative approaches, such as neoadjuvant or adjuvant therapy, remains the clinical objective.

John M. Burke, MD, discusses how Bruton tyrosine kinase inhibitors have demonstrated unexpected promise in treating follicular lymphoma, challenging previous assumptions in the field of oncology.

Robert Dreicer, MD, MS, MACP, FASCO, acknowledges that there have been substantial developments in therapies and strategies for treating prostate cancer, leading to heightened expectations of breakthroughs in the field.